PMV Pharmaceuticals reports news as a precision oncology company developing small molecule therapies that target p53. Its recurring updates center on rezatapopt, an oral product candidate designed to reactivate mutant p53 in tumors with the TP53 Y220C mutation, and on the PYNNACLE clinical trial in advanced solid tumors, including ovarian cancer.
Company announcements also cover clinical data presentations and publications, FDA designation activity, periodic financial results, research and development spending tied to rezatapopt, cash runway commentary, and board governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced progress in its Phase 1/2 PYNNACLE study of PC14586, aimed at advanced solid tumors with a p53 Y220C mutation. The company has enrolled the first patient in a combination study with KEYTRUDA. As of December 31, 2022, PMV reported cash and equivalents of $243.5 million, a decline from $314.1 million in 2021, with a net loss of $73.3 million for the year compared to a loss of $57.8 million in 2021. R&D expenses increased to $52.0 million, mainly due to expanding clinical efforts. The firm continues to focus on PC14586 and expects further updates in the second half of 2023.
PMV Pharmaceuticals (Nasdaq: PMVP) is set to participate in two key investor conferences in March 2023. CEO David H. Mack will represent the company at Cowen’s 43rd Annual Health Care Conference on March 8, where he'll join a panel discussing tumor diagnostic development at 9:10 AM ET. Following this, he will take part in Oppenheimer’s 33rd Annual Healthcare Conference on March 13, featuring a fireside chat at 8 AM ET. PMV Pharma specializes in developing small molecule, tumor-agnostic therapies targeting p53, a protein associated with nearly half of all cancers. For more information, visit www.pmvpharma.com.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology firm, announced that CEO David H. Mack, Ph.D., will join a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference, scheduled for November 29 – December 1, 2022. The conference will focus on PMV Pharma's pioneering work in small molecule, tumor-agnostic therapies targeting p53, a protein associated with roughly half of all cancers. Investors will also have opportunities for one-on-one meetings during the event.